01808nas a2200289   4500000000100000008004100001260001200042653001800054653001400072653002000086653002300106653001200129100001600141700001600157700001300173700001400186700001400200700002800214700001400242700002000256700001600276700001300292700001200305245008600317520110100403022001401504       2020                            d  c12/202010aCarbohydrates10adiagnosis10aglycoconjugates10alateral flow assay10aleprosy1 avan Dijk HJ1 avan Hooij A1 aGroot ML1 aGeboers J1 aMoretti R1 aVerhard-Seymonsbergen E1 ade Jong D1 avan der Marel G1 aCorstjens P1 aCodée J1 aGeluk A00aSynthetic Phenolic Glycolipids for application in diagnostic tests  for leprosy.3 a<p>Point-of-care (POC) diagnostic tests for rapid detection of individuals infected with Mycobacterium leprae ( M. leprae) , the causative pathogen of leprosy, represent efficient tools to guide therapeutic and prophylactic treatment strategies in leprosy control programs, thus positively contributing to clinical outcome and reduction of transmission of this infectious disease. Levels of antibodies directed against the M. leprae -specific phenolic glycolipid I (PGL-I) closely correlate with an individual's bacterial load and higher risk of developing leprosy. We here describe the assembly of a set of PGL glycans carrying the characteristic phenol aglycon and featuring different methylation patterns. The PGL trisaccharides were applied to construct neoglycoproteins that were used to detect anti-PGL IgM antibodies in leprosy patients. ELISAs and quantitative lateral flow assays based on up-converting nanoparticles (UCP-LFAs) showed that the generated PGL-I and PGL-II trisaccharide neoglycoconjugates can be applied for the detection of anti M. leprae IgM antibodies in POC tests.</p>  a1439-7633